In this model of hepatic micrometastases, the antitumor efficacy and role of the T-cell and natural killer (NK) cell populations were studied for oncolytic herpes simplex virus type-1 (HSV-1) viral mutants containing the granulocyte-monocyte colony stimulating factor (GM-CSF (NV1034)) or interluken-12 (IL-12 (NV1042)) cytokine genes. These were compared to saline and control virus (NV1023) in vitro and in vivo. HSV-1 mutants were assessed for cytotoxicity, replication and cytokine expression in CT-26 cells. A syngeneic micrometastatic liver model was then established in naive and immune cell-depleted animals to assess the antitumor efficacy of these viruses. In vitro cytotoxicity and viral replication were similar for each virus, resulting in greater than 80 and 98% cytotoxicity at multiplicity of infection of 1 and 10, respectively. Peak viral titers were 25-to 50-fold higher than initial titer and were not significantly different between viruses. In vivo, all three viruses reduced metastases relative to control, but cytokinesecreting viruses did so with greater efficacy compared to NV1023. This effect was abrogated by T-cell depletion, but not NK-cell depletion. Single-agent therapy with oncolytic viral agents containing GM-CSF or IL-12 is effective in a murine model of liver metastases and likely involves direct viral oncolysis and actions of specific immune effector cells.
Introduction
Oncolytic viral therapy with herpes simplex virus type-1 (HSV-1) viral mutants has been shown to be an effective strategy for lysing tumor cells in vitro and in multiple experimental animal models. [1] [2] [3] [4] [5] [6] [7] Several of these oncolytic mutants have even been utilized in human clinical trials for malignant brain tumors and colorectal liver metastases, some with quite promising results. 8, 9 The ability of these viruses to eradicate tumor is believed to be dependent on the viral replication cycle, in which viral replication produces multiple progeny virions that infect neighboring cells after cell lysis, rather than the expression of particular viral genes.
Cytokine gene therapy for the treatment of cancer has also been extensively studied and may ultimately prove quite effective. Among the most studied cytokines for this purpose are granulocyte-monocyte colony stimulating factor (GM-CSF) and interleukin-12 (IL-12). GM-CSF is a cytokine secreted by a large number of cell types, including activated lymphocytes, macrophages and endothelial cells, and whose primary effects include recruitment and differentiation of antigen-presenting cells and production of marrow-derived myeloid cells. 10 Several groups have delivered GM-CSF in animal models via adenoviral or retroviral vectors or by transduced tumor cells and achieved systemic and prolonged antitumor immunity, [11] [12] [13] [14] [15] while others have even used irradiated tumor cells engineered to secrete GM-CSF in phase I human clinical trials. 16 IL-12 is a proinflammatory cytokine secreted by activated macrophages and dendritic cells which have important stimulatory effects on T cells and natural killer (NK) cells and can mediate anti-angiogenesis effects via elaboration of gammainterferon (IFN-g) and other downstream effector molecules. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Like GM-CSF, IL-12 has been shown to induce antitumor immunity when delivered to tumor by adenoviral vectors or other strategies. [27] [28] [29] [30] [31] [32] [33] [34] We have begun to investigate the potential to combine oncolytic viral therapy with cytokine gene therapy by treating a murine model of micrometastatic liver disease with oncolytic HSV-1 mutants genetically engineered to express the murine GM-CSF and IL-12 cytokine genes. Replication-competent oncolytic viral mutants have previously been combined with replication-defective vectors expressing cytokine genes in flank tumor models. 35 Our group and others have shown efficacy of singleagent therapy with replication-competent HSV-1 mutants containing cytokine genes in murine flank tumor and intracranial models using colorectal, squamous, glioma and neuroblastoma cell lines. [36] [37] [38] [39] The current experiments, however, demonstrate encouraging results with these constructs in a more clinically relevant model of micrometastatic liver disease analogous to the micrometastatic disease believed to be the source of local failure after liver resection for metastatic colon cancer. Furthermore, these experiments illustrate the elaboration of immunostimulatory and anti-angiogenic cytokines caused by these viruses as well as the contributions of T-cell and NK-cell populations to the effect of the viruses.
Materials and methods

Cell culture
The CT-26 murine colorectal cancer cell line was obtained from American Type Culture Collection (ATCC, Rockville, MD) and maintained in RPMI media supplemented with 10% fetal calf serum (FCS), 5 mmol/l nonessential amino acids and 1% penicillin and streptomycin. Cells were kept in culture at 371C in a 5% CO 2 -humidified incubator.
Viruses NV1023, NV1034 and NV1042 are oncolytic HSV-1 viral mutants whose construction has been described previously by our laboratory. 38, 39 NV1023 differs from wild-type HSV-1 by the insertion of the Escherichia coli lac Z reporter gene into the a47 locus thus resulting in the deletion of the g 1 34.5 gene and the a4 promoter ( Figure 1 ). NV1023 serves as the control virus for NV1034 and NV1042, which have identical structure except for the insertions of the a4-driven murine GM-CSF (mGM-CSF) and IL-12 genes, respectively. Cytokine quantification by ELISA Supernatants from cytotoxicity assays were harvested and stored at À201C as described above until assayed for in vitro cytokine quantification. Murine GM-CSF and IL-12 concentration was determined by enzyme-linked immunosorbent assay (ELISA) (Quantikine Kit, R&D Systems, Minneapolis, MN, USA) according to manufacturer protocol for cells infected with NV1023, NV1034 and NV1042 at an MOI of 1. Results were expressed as nanograms of cytokine per milliliter of supernatant. In vivo cytokine production was performed on serum and liver samples obtained from animals at 1, 2, 3 and 10 days after treatment with 1 Â 10 7 plaque-forming units (pfu) of NV1034 or NV1042 virus. Livers from sacrificed animals were harvested and frozen in liquid nitrogen, then stored at À801C. Frozen samples were then homogenized with T-PER Tissue Protein Extraction Reagent (Pierce, Rockford, IL, USA) and assayed for cytokine level by ELISA. Blood collected by retro-orbital bleed was centrifuged, and serum was collected and stored at À201C. Serum was then assayed undiluted by ELISA.
Cytotoxicity assays and viral growth analysis
Animal studies
All animal work was approved by the Memorial SloanKettering Institute Animal Care Committee and performed under strict guidelines. Balb/c mice (4-6 weeks old) were purchased from Taconic (Germantown, NY, USA) and housed five per cage and allowed access to food and water ad libitum. Surgical procedures were done under sterile conditions with intraperitoneal ketaminexylazine anesthesia.
Tumor inoculation was performed by laparotomy and injection of 5 Â 10 4 CT-26 cells into the exteriorized inferior pole of the spleen in 250 ml of serum-free media. Figure 1 Genetic composition of wild-type HSV-1 (F-strain) and viral mutants NV1023, NV1034 and NV1042. Wild-type HSV has unique long (UL) and unique short (US) sequences flanked by inverted repeats (a-c). Viruses used in these experiments have a portion of the HSV-2 genome inserted into the inverted repeat sequence, thus deleting one copy of the g 1 34.5 virulence factor gene, and an insertion of the E. coli lac Z reporter gene into the a47 locus. Furthermore, NV1034 has an insertion of the murine GM-CSF gene under control of the hybrid a4-thymidine kinase (TK) promotor into the HSV-2 region. NV1042 has the murine IL-12 gene inserted into this region instead. HSV: herpes simplex virus.
The spleen was then returned to the abdomen and the incision was closed with absorbable suture and wound clips. This technique reliably establishes 100-250 metastatic liver nodules by 2 weeks at which point control animals also began to show the deleterious effect of the tumor burden with failure to groom, changes in feeding behavior and weight loss.
To simulate the treatment of micrometastatic disease, animals receive viral therapy 24 h after tumor inoculation. Animals undergo repeat laparotomy and intrasplenic injection of phosphate-buffered saline (PBS) (control), or 1 Â 10 7 pfu of NV1023, NV1034 or NV1042 (n ¼ 16 per group). Animals are then followed for two weeks, at which point they are sacrificed by CO 2 inhalation, livers are harvested and liver surface nodules are counted by the author and a blinded assistant.
For T-cell depletion studies (n ¼ 16 per group), animals receive 0.2 mg/day of anti-GK1.5 (anti-CD4 þ ) and anti-53-6.72 (anti-CD8 þ ) antibodies (Memorial Sloan-Kettering Monoclonal Antibody Core Facility, New York, NY, USA) via daily intraperitoneal injection for 3 days prior to initiation of the experiment and weekly thereafter. For NK-cell depletion studies (n ¼ 8 per group), animals received 40 ml of anti-asialo GM1 antibodies 2 days prior to initiation of the experiment, then every 5 days thereafter.
To assess toxicity of such viral administration, separate mice were also injected splenically with 1 Â 10 7 plaque-forming units of NV1034 or NV1042. Animals were sacrificed at 1, 3, 7 and 14 days and serum assessed for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by standard spectrophotometric analysis (Sigma).
Statistical analysis
All data are expressed as the mean7s.e.m. Comparisons between groups were made using a two-tailed Student's t-test. An analysis of variance test, where appropriate, was used to identify statistical significance for multiple comparisons. Statistical significance was defined as Po0.05.
Results
In vitro experiments
Cytotoxicity experiments demonstrated that all three viruses showed similar oncolytic efficacy against the CT-26 cell line in vitro (Figure 2 ). Cell viability was 86, 98 and 95% of control wells at day 5 after infection with NV1023, NV1034 and NV1042, respectively, at an MOI of 0.1. Infection at an MOI of 1 had an intermediate cytotoxic effect for all viruses, leading to cell viability between 4 and 20% of control wells by day 5. The strongest cytotoxic effect was seen at an MOI of 10, as cell viability was reduced to less than 5% of control wells by day 3 and less than 1% by day 5 for all three viruses.
As with cytotoxicity, viral growth curve analysis showed no significant differences between viral proliferation of NV1023, NV1034 and NV1042 in the CT-26 cell line (Figure 3) . By 24 h postinfection, viral titers rise until reaching peak levels between 5 and 6 days. Peak titers were 25-to 50-fold higher than initial infecting titer and were not significantly different between the three viruses (P40.08). After reaching peak levels, viral titer decreases due to a sharp decline in the number of remaining viable cells. In vitro cytokine quantitation by ELISA (Figure 4 ) demonstrated maximal cytokine production at an MOI of 1 for both NV1034 and NV1042, as higher MOI resulted in increased cell death and thus a plateau in cytokine level after day 1. Cells infected with NV1034 at an MOI of 1 secreted mGM-CSF by day-3 postinfection, and maximal cytokine production reached 3.7 ng/ml on day 5 (Figure 4a ). Cells infected with NV1042 at an MOI of 1 secreted mIL-12 by as early as day-1 postinfection, and achieved a maximal cytokine concentration of 10 ng/ml between days 4 and 5 ( Figure 4b ). Cells infected with NV1023 did not produce detectable levels of mGM-CSF or mIL-12 at any time point.
In vivo experiments
In the toxicity experiment group, the injections of NV1034 or NV1042 did not provide clinically significant hepatotoxicity. Serum ALT and AST levels rose from a baseline of 3774 and 2073 U/liter respectively to approximately 3 and 5 times baseline (120735 and 97730 U/liter) at day 1, but returned to baseline by day 7.
At the 2-week sacrifice point, 38.4% of the control (PBS) animals compared to 14.3% of NV1023 animals, 6.7% of NV1034 animals and none of the NV1042 animals revealed failure to groom, change in feeding behavior or weight loss consistent with tumor cachexia (Po0.05). All virally treated animal groups showed a significant reduction in the mean number of surface liver nodules compared to treatment with PBS alone (Table 1) . Moreover, animals treated with either cytokine-secreting virus, NV1034 or NV1042 showed a significantly lower tumor burden relative to those animals treated with control virus NV1023 (mean of 54 and 13 vs 101 surface nodules per group, respectively; Po0.001). Figure 3 Viral proliferation of NV1023, NV1034 and NV1042 in the CT-26 cell line. Viral titer initially decreases due to viral uptake and disassembly as seen at the 6 and 24 h time points. Titer then increases over the next several days, reaching peak levels, which are 25-to 50-fold higher than initial infecting titer. There are no statistically significant differences between peak viral titers for the three viruses (P40.08). Figure 4 Cumulative in vitro cytokine production by CT-26 cells infected with NV1023, NV1034 and NV1042 at MOI ranging from 0.1 to 10. Cells infected with NV1023 did not produce detectable levels of GM-CSF (a) or IL-12 (b) at any measured time point. Maximal GM-CSF production occurred in cells infected with NV1034 at an MOI of 1 (a), while the same MOI resulted in maximal IL-12 production (b) in cells infected with NV1042. Although increasing MOI to 10 resulted in earlier GM-CSF and IL-12 production, the greater cytotoxic effect of the virus on the cells caused lower cumulative cytokine levels over the 5-day experiment. MOI: multiplicities of infection.
As Figure 5 demonstrates, T-cell depletion resulted in significantly increased tumor burden in all virally treated groups. Furthermore, T-cell depletion abolished the increased efficacy of NV1034 relative to NV1023 (mean of 105 vs 131 surface nodules per group; NS, P40.05). NV1042 continued to suppress micrometastases better than NV1023; however, the difference was less pronounced than in the undepleted groups (mean of 31 vs 131 nodules per group; Po0.001).
NK-cell depletion studies were performed to delineate the role of this cell population in the effects of NV1042, as T-cell depletion did not completely abolish the increased efficacy of NV1042 relative to the control virus NV1023. Figure 6 illustrates the results of this experiment, which show that NK-cell depletion by administration of antiasialo GM1 antibodies did not diminish the efficacy of any of the viral treatments relative to control. Furthermore, both NV1034 and NV1042 continue to suppress metastases more efficiently than NV1023, and there is no statistically significant difference between NK-depleted and naive groups.
Quantification of tissue cytokine levels was performed on serum and livers harvested at 1, 2, 3 and 10 days after viral treatment (Figure 7) . Importantly, NV1023 did not induce IL-12, GM-CSF or IFN-g production in tissue samples except for a modest production of IL-12 (approximately 100 pg/g of liver) at day 10 after treatment. NV1034, however, induced GM-CSF in both serum and liver with peak levels in both tissues occurring at day 2 ( Figure 7a ). NV1034 did not induce IFN-g except for low levels (approximately 120 pg/g of liver) at day 10. NV1042 not only induced production of IL-12 in large amounts in the serum and liver, but it also caused strong induction of IFN-g over multiple time points (Figure 7b) . Levels of both of these cytokines were similar in serum and liver, and peak expression again occurred at day 2 and then decreased.
Discussion
The potential to treat malignancies with attenuated replication-competent oncolytic HSV-1 has been demonstrated in a number of cell lines in experimental flank, Figure 5 Liver surface nodule counts for naive (open bars) and T-cell depleted (solid bars) Balb/C mice after splenic inoculation with CT-26 cells followed by treatment with PBS or 1 Â 10 7 pfu of appropriate virus at 24 h. T-cell depletion resulted in significantly increased nodule counts for all virally treated groups. Furthermore, animals treated with NV1034 continued to show significantly reduced tumor burden than control animals, but not compared to animals treated with NV1023. Antitumor effects of NV1042 were partially abrogated by T-cell depletion, but significant tumor volume reductions were still seen in this group relative to control and NV1023 treated groups. pfu: plaque-forming unit. Figure 6 Liver surface nodule counts for naive (open bars) and NK-cell depleted (solid bars) Balb/c mice after splenic inoculation with CT-26 cells followed by treatment with PBS or 1 Â 10 7 pfu of appropriate virus at 24 h. NK-cell depletion did not abrogate effects of any of the viruses, as no significant differences exist between naive and depleted groups. pfu: plaque-forming unit. Abbreviations: GM-CSF, granulocyte-monocyte colony stimulating factor; IL-12, interleukin 12. *Po0.01 vs PBS group; **Po0.001 vs PBS and NV1023 groups. Average liver surface nodule counts for Balb/C mice after splenic inoculation with CT-26 cells followed by PBS or viral treatment at 24 h. All virally treated groups suppressed liver metastases compared to PBS-treated animals, and treatment with NV1034 and NV1042 showed better efficacy than control virus NV1023.
bladder, peritoneal, pleural, liver and brain models in animals. [1] [2] [3] [4] [5] [6] [7] Several human clinical trials have been performed with these agents as well, including an ongoing study at our institution in patients with unresectable colorectal liver metastases. 2, 8 The mechanism of oncolysis is presumably direct cell lysis caused by replication of the virus within tumor cells. Although wild-type HSV-1 itself shows affinity for rapidly dividing cells, the commonly studied viral agents have mutations which increase tumor specificity, such as deletion of the viral ribonucleotide reductase gene, or which decrease virulence, such as deletions of the virulence factor genes g 1 34.5 and infected cell protein 47. 40 A different type of genetic modification of these oncolytic viruses involves the insertion of exogenous genes which encode suicide predrug catalysts, anti-angiogenesis factors, chemokines or cytokines.
The use of cytokines, including GM-CSF and IL-12 in particular, in anticancer therapy has received considerable support in experimental models. GM-CSF is secreted primarily by activated lymphocytes and macrophages, and causes multiple immunostimulatory effects, including recruitment of antigen-presenting cells and stimulation of cells of the myeloid lineage.
10 IL-12 is a heterodimeric cytokine consisting of 35-and 40 kDa subunits which is secreted by antigen-presenting cells. IL-12 stimulates both T cells and NK cells, causing increased recruitment and activity of each. [21] [22] [23] [24] [25] [26] IL-12 also has been shown to have anti-angiogenic effects via induction of IFN-g and IP-10, and downregulation of other pro-angiogenic mediators like vascular endothelial growth factor (VEGF) and MMP-9. [17] [18] [19] [20] Multiple groups have demonstrated systemic and sustained antitumor immunity in experimental models using adenovirus, retrovirus or irradiated tumor cells that express GM-CSF in vivo.
11-15 Similar techniques have also been successful in blood-borne and solid tumors when used to present IL-12 to the host. [27] [28] [29] [30] [31] [32] [33] [34] Although there have been previous attempts at combining replication-competent oncolytic HSV with replication-defective HSV vectors encoding GM-CSF or IL-12, 35 there have been few studies involving single agent viral oncolytics expressing cytokine genes. [36] [37] [38] [39] While our laboratory has had previous experience using these agents in flank tumor models with several cell lines, [36] [37] [38] [39] this current study assesses the ability of these oncolytic HSV to treat tumor in a more clinically relevant model of liver metastases.
In these experiments we have demonstrated similar cytotoxicity and viral replication between the three HSV-1 mutants NV1023, NV1034 and NV1042 in the murine CT-26 colorectal cancer cell line. Cytokine quantitation of the supernatants of cells infected with these viruses showed high expression (nanogram levels) of GM-CSF and IL-12 for NV1034 and NV1042, respectively, and no cytokine induction by the control virus, NV1023. Thus, the insertion of the cytokine genes did not mitigate the in vitro oncolytic effects of the viruses but did allow them to function as vectors for important immunostimulatory molecules.
The effects of these immunostimulatory cytokines are illustrated in the animal studies in which hepatic metastases are suppressed by viral treatment. This is an important model because it is analogous to patients who have micrometastatic disease left behind at the time of surgical resection of liver lesions. This common problem is believed to be contributory to local recurrence after undergoing an attempt at curative operation. 41 The results show that while treatment with each of the three viruses reduces liver tumor burden, treatment with the cytokine-secreting viruses was more effective than treatment with NV1023, which does not contain any immunomodulatory cytokine genes. Results of the depletion studies suggest that the in vivo differences between these viruses were dependent upon cytokine expression or immune stimulation, as the removal of the T-cell population decreased the efficacy of both NV1034 and NV1042. In fact, T-cell depletion eliminated the statistically significant difference in tumor burden between animals treated with NV1023 and NV1034, suggesting that perhaps NV1034 differs from the control virus only by its effect on T cells. NV1042 continued to show increased efficacy relative to NV1023 after T-cell depletion, thus prompting investigation of the potential mechanisms by which Figure 7 Induction of in vivo cytokine expression by NV1034 and NV1042 in serum and liver samples. Treatment with 1 Â 10 7 pfu of NV1034 resulted in peak GM-CSF expression at 48 h after virus administration (a). IFN-g production was seen only at the day 10 time point with NV1034 treatment, whereas treatment with 1 Â 10 7 pfu of NV1042 resulted in IFN-g levels in both serum and liver which exceeded IL-12 levels (b). IFN-g and IL-12 followed the same pattern of expression and showed peak levels at 48 h. pfu: plaque-forming unit.
NV1042 exerts its antitumor effects. Although IL-12 has been demonstrated to induce NK-cell activation, NK-cell depletion studies performed here suggest that this cell population is not involved in the actions of NV1042 in this model. NK-cell depletion did not reduce the efficacy of NV1042 relative to PBS or control virus, and there were no differences between NK cell depleted and naive groups.
Another plausible mechanism for the effects of NV1042 includes the anti-angiogenic properties of IL-12. In a previous study, we have demonstrated that secretion of IL-12 by NV1042 results in tumor regression partly by this anti-angiogenic action. 42 This cytokine has been shown to have both direct modulatory effects on downstream angiogenic mediators and to induce IFN-gdependent regulation of VEGF and other effector molecules. 18, 20 In our experiments, tissue cytokine quantification performed on serum and livers of animals treated with NV1042 revealed not only IL-12 but also strong IFN-g elaboration.
In conclusion, we have demonstrated that single-agent therapy with an attenuated replication-competent oncolytic HSV encoding GM-CSF or IL-12 can be used effectively for suppression of liver metastases in a clinically relevant murine model. In addition to direct viral oncolysis, these viruses appear to have T-cell, but not NK-cell-mediated components to their antitumor activity. Further research is warranted to more fully investigate the anti-angiogenic effects of the NV1042 mutant, as the strong induction of the IFN-g cytokine could potentially modulate other angiogenic molecules.
